Rigel Pharmaceuticals Inc. (New) (RIGL) is a publicly traded Healthcare sector company. As of May 21, 2026, RIGL trades at $28.74 with a market cap of $529.34M and a P/E ratio of 1.41. RIGL moved +2.08% today. Year to date, RIGL is -30.03%; over the trailing twelve months it is +43.24%. Its 52-week range spans $13.57 to $52.24. Analyst consensus is buy with an average price target of $54.00. Rallies surfaces RIGL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rigel Secures VEPPANU License with $70M Upfront, $320M Milestones: Rigel will pay $70M upfront plus $320M in milestones for exclusive global rights to VEPPANU, the first FDA-approved PROTAC for ER+/HER2-, ESR1-mutated breast cancer. Phase 3 VERITAC-2 showed median PFS of 5.0 vs. 2.1 months—a 43% risk reduction—as VEPPANU becomes Rigel’s fourth commercial product and core revenue driver.
| Metric | Value |
|---|---|
| Price | $28.74 |
| Market Cap | $529.34M |
| P/E Ratio | 1.41 |
| EPS | $20.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $52.24 |
| 52-Week Low | $13.57 |
| Volume | 669 |
| Avg Volume | 0 |
| Revenue (TTM) | $299.77M |
| Net Income | $364.23M |
| Gross Margin | 93.39% |
4 analysts cover RIGL: 0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $54.00.